Please assess the completion status of the following clinical trial:

Trial Title: A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of ischemic stroke for longer than 6 months~* Brain CT/MRI scan at initial diagnosis and at enrollment consistent with ischemic stroke~* No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment~* NIHSS score between 6-20~* Life expectancy greater than 12 months~* Prior to treatment patient received standard medical care for the secondary prevention of ischemic stroke~* Adequate organ function as defined by the following criteria:~Exclusion Criteria:~* History of uncontrolled seizure disorder~* History of cancer within the past 5 years.~* History of cerebral neoplasm~* Positive for hepatitis B, C or HIV~* Myocardial infarction withing six months of study entry~* Findings on baseline CT suggestive of subarachnoid or intracerebral hemorrhage within past 12 months.~* Allergies to Bovine or Porcine products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stem cells (Type: EXPERIMENTAL): All subjects will receive allogeneic adult mesenchymal bone marrow stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).